PL2992017T3 - Przeciwciała skierowane przeciwko receptorowi programowanej śmierci-1 (pd-1) - Google Patents

Przeciwciała skierowane przeciwko receptorowi programowanej śmierci-1 (pd-1)

Info

Publication number
PL2992017T3
PL2992017T3 PL14791454T PL14791454T PL2992017T3 PL 2992017 T3 PL2992017 T3 PL 2992017T3 PL 14791454 T PL14791454 T PL 14791454T PL 14791454 T PL14791454 T PL 14791454T PL 2992017 T3 PL2992017 T3 PL 2992017T3
Authority
PL
Poland
Prior art keywords
programmed death
targeted against
antibodies targeted
against programmed
antibodies
Prior art date
Application number
PL14791454T
Other languages
English (en)
Inventor
David J. King
Marilyn Kehry
Original Assignee
Anaptysbio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio, Inc. filed Critical Anaptysbio, Inc.
Publication of PL2992017T3 publication Critical patent/PL2992017T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14791454T 2013-05-02 2014-05-02 Przeciwciała skierowane przeciwko receptorowi programowanej śmierci-1 (pd-1) PL2992017T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818755P 2013-05-02 2013-05-02
PCT/US2014/036525 WO2014179664A2 (en) 2013-05-02 2014-05-02 Antibodies directed against programmed death-1 (pd-1)
EP14791454.3A EP2992017B1 (en) 2013-05-02 2014-05-02 Antibodies directed against programmed death-1 (pd-1)

Publications (1)

Publication Number Publication Date
PL2992017T3 true PL2992017T3 (pl) 2021-09-06

Family

ID=51844119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14791454T PL2992017T3 (pl) 2013-05-02 2014-05-02 Przeciwciała skierowane przeciwko receptorowi programowanej śmierci-1 (pd-1)

Country Status (25)

Country Link
US (4) US9815897B2 (pl)
EP (2) EP2992017B1 (pl)
JP (2) JP6742903B2 (pl)
KR (1) KR102243062B1 (pl)
CN (1) CN105339389B (pl)
AU (2) AU2014259719B2 (pl)
CA (1) CA2910278C (pl)
CY (2) CY1123935T1 (pl)
DK (1) DK2992017T3 (pl)
ES (1) ES2845609T3 (pl)
HR (1) HRP20210122T1 (pl)
HU (2) HUE053069T2 (pl)
LT (2) LT2992017T (pl)
LU (1) LUC00232I2 (pl)
MX (1) MX372817B (pl)
NL (1) NL301120I2 (pl)
NO (1) NO2021043I1 (pl)
PL (1) PL2992017T3 (pl)
PT (1) PT2992017T (pl)
RS (1) RS61400B1 (pl)
RU (1) RU2723050C2 (pl)
SG (1) SG11201508528TA (pl)
SI (1) SI2992017T1 (pl)
SM (1) SMT202100065T1 (pl)
WO (1) WO2014179664A2 (pl)

Families Citing this family (429)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
KR102243062B1 (ko) * 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
CN114591433A (zh) * 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
HUE055207T2 (hu) * 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017031242A1 (en) * 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CN114605548A (zh) * 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
JP2018529719A (ja) * 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
SMT202200118T1 (it) * 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
MA44146B1 (fr) 2015-12-22 2023-10-31 Regeneron Pharma Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
JP2019509759A (ja) * 2016-01-14 2019-04-11 ビーピーエス バイオサイエンス、インク．Ｂｐｓ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． 抗ｐｄ−１抗体及びその使用
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
US10294299B2 (en) 2016-01-22 2019-05-21 MabQuest SA Immunological reagents
EP3416982A1 (en) 2016-02-17 2018-12-26 Novartis AG Tgfbeta 2 antibodies
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
EP3848393A1 (en) * 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
FI3464368T3 (fi) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
JP7175198B2 (ja) 2016-06-02 2022-11-18 ブリストル－マイヤーズ スクイブ カンパニー 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断
EP3988570A1 (en) 2016-06-03 2022-04-27 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
EP3464369A1 (en) 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
CN109475634A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
JP2019517557A (ja) 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MA45999A (fr) 2016-08-22 2019-06-26 Arbutus Biopharma Corp Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
CN107814845B (zh) * 2016-09-14 2021-02-09 浙江特瑞思药业股份有限公司 新的抗pd-1纳米抗体及其应用
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
KR20240019398A (ko) 2016-10-28 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
WO2018119474A2 (en) * 2016-12-23 2018-06-28 Remd Biotherapeutics, Inc. Immunotherapy using antibodies that bind programmed death 1 (pd-1)
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
BR112019014187A2 (pt) * 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
EP3568412A2 (en) 2017-01-13 2019-11-20 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
WO2018133842A1 (zh) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
PT3579874T (pt) 2017-02-10 2021-10-07 Novartis Ag 1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018160540A1 (en) 2017-02-28 2018-09-07 Sanofi Therapeutic rna
IL269026B2 (en) 2017-03-31 2024-12-01 Bristol Myers Squibb Co Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
SG10201913677SA (en) 2017-04-27 2020-03-30 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
US12156872B2 (en) 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
US20210340250A1 (en) 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
WO2018223040A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
AU2018301810A1 (en) 2017-07-13 2020-01-23 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CN111793060B (zh) 2017-07-14 2023-06-06 先天肿瘤免疫公司 Nlrp3调节剂
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
KR20200052327A (ko) 2017-09-04 2020-05-14 아게누스 인코포레이티드 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
WO2019067913A1 (en) 2017-09-29 2019-04-04 Bristol-Myers Squibb Company COMPOSITIONS AND METHODS OF TREATING CANCER
CN111372607A (zh) 2017-09-30 2020-07-03 特沙诺有限公司 用于治疗癌症的联合疗法
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR102747388B1 (ko) 2017-10-16 2024-12-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
SG11202003626RA (en) 2017-11-06 2020-05-28 Bristol Myers Squibb Co Methods of treating a tumor
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US11306119B2 (en) 2017-12-15 2022-04-19 Kyungpook National University Industry-Academic Cooperation Foundation Peptide bound to PD-L1 and use thereof
EP3731866A1 (en) 2017-12-27 2020-11-04 Tesaro Inc. Methods of treating cancer
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
WO2019144126A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111629731A (zh) 2018-01-22 2020-09-04 百时美施贵宝公司 治疗癌症的组合物和方法
MA51679A (fr) 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
MY210421A (en) 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
IL302626B2 (en) 2018-01-26 2025-12-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
CA3090479A1 (en) 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7110369B2 (ja) * 2018-02-23 2022-08-01 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｐｄ－１抗体及びその用途
WO2019173587A1 (en) 2018-03-08 2019-09-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019195452A1 (en) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
JP7054573B2 (ja) 2018-04-15 2022-04-14 イムヴィラ・カンパニー・リミテッド Ｐｄ－１結合抗体及びその用途
JP7351850B2 (ja) 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３修飾因子
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CN120714023A (zh) 2018-06-20 2025-09-30 因赛特公司 抗pd-1抗体及其用途
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
EP3823991A4 (en) * 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
SG11202100693UA (en) 2018-07-26 2021-02-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer
WO2020037091A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
WO2020037094A1 (en) 2018-08-16 2020-02-20 Innate Tumor Immunity, Inc. Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
KR102817037B1 (ko) 2018-08-16 2025-06-04 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
WO2020072796A1 (en) 2018-10-03 2020-04-09 Tesaro, Inc. Crystalline forms of niraparib freebase
TWI853841B (zh) 2018-10-03 2024-09-01 美商提薩羅有限公司 尼拉帕尼（niraparib）鹽
EP3864046A1 (en) 2018-10-09 2021-08-18 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CA3117016A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
US12479917B2 (en) 2018-10-23 2025-11-25 Bristol-Myers Squibb Company Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
CA3116564A1 (en) * 2018-11-19 2020-05-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pd-1 antibodies and uses thereof
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
PL3894012T3 (pl) 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
AU2019406840A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
MX2021007271A (es) 2018-12-21 2021-07-15 Onxeo Nuevas moleculas de acido nucleico conjugado y sus usos.
MX390775B (es) * 2018-12-21 2025-03-21 Ose Immunotherapeutics Anticuerpo humanizado anti-pd-1 humana
EP3899951A1 (en) 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Tumor classification based on predicted tumor mutational burden
CN113301962A (zh) 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
JP7373571B2 (ja) 2019-01-14 2023-11-02 イネイト・テューマー・イミュニティ・インコーポレイテッド がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
JP7506080B2 (ja) 2019-01-14 2024-06-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
KR102865929B1 (ko) 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
TWI850316B (zh) 2019-01-21 2024-08-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性rna及抗pd1抗體
CN113710322A (zh) 2019-01-25 2021-11-26 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
KR20210126652A (ko) 2019-02-12 2021-10-20 노파르티스 아게 Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CN113677402A (zh) 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法
CN113891748A (zh) 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
MX2021012692A (es) 2019-04-19 2021-11-12 Genentech Inc Anticuerpos anti-mertk y sus metodos de uso.
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US20220319704A1 (en) 2019-05-06 2022-10-06 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
GEAP202415849A (en) 2019-06-03 2024-03-11 Exelixis Inc Crystalline salt forms of kinase inhibitor
AR119069A1 (es) 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
EP3986454A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
JP7771749B2 (ja) 2019-08-08 2025-11-18 小野薬品工業株式会社 二重特異性タンパク質
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
EP4034248A1 (en) 2019-09-25 2022-08-03 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
EP4034154A1 (en) 2019-09-25 2022-08-03 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
JP2022553821A (ja) 2019-11-05 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー Ｍ－タンパク質アッセイおよびその使用
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
EP4058435A1 (en) 2019-11-13 2022-09-21 Genentech, Inc. Therapeutic compounds and methods of use
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
TW202133887A (zh) 2019-12-09 2021-09-16 美商西健公司 使用liv1-adc及pd-1拮抗劑之組合療法
CA3164600A1 (en) 2019-12-18 2021-06-24 Tesaro, Inc. Biopharmaceutical compositions and related methods
WO2021127200A1 (en) 2019-12-19 2021-06-24 Ngm Biopharmaceuticals, Inc. Ilt3-binding agents and methods of use thereof
JP2023510108A (ja) 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
EP4087842A1 (en) 2020-01-10 2022-11-16 Innate Tumor Immunity, Inc. Nlrp3 modulators
MX2022008763A (es) 2020-01-17 2022-07-27 Novartis Ag Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
KR20220133996A (ko) 2020-01-30 2022-10-05 오엔에이 테라퓨틱스 에스.엘. 암 및 암 전이를 치료하기 위한 병용 요법
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
US11577665B2 (en) 2020-02-27 2023-02-14 Cpk Interior Products Urethane and graphene interior trim panel
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
BR112022017637A2 (pt) 2020-03-06 2022-11-08 Celgene Quanticel Res Inc Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas
JP2023516724A (ja) 2020-03-06 2023-04-20 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
TW202202521A (zh) 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 用於治療癌症之抗ccr8抗體
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021260982B2 (en) 2020-04-21 2024-03-28 Novartis Ag Dosing regimen for treating a disease modulated by CSF-1R
CA3181197A1 (en) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof
CA3181538A1 (en) 2020-05-05 2021-11-11 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
TW202216768A (zh) 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Ｌａｉｒ－１結合劑及其使用方法
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023531537A (ja) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ 卵巣癌ワクチンでの白血病由来細胞の使用
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
AU2021318134A1 (en) 2020-07-31 2023-03-02 Exelixis, Inc. Combinations for the treatment of cancer
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2022040555A2 (en) 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
AU2021330087B2 (en) * 2020-08-31 2025-10-23 Biosion Inc. PD-1 binding antibodies and uses thereof
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022049526A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
EP3970489A1 (en) 2020-09-18 2022-03-23 CpK Interior Products Inc. Graphene-based antiviral polymer
MX2023003414A (es) 2020-09-24 2023-04-14 Merck Sharp & Dohme Llc Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y metodos de uso de las mismas.
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20230098279A (ko) 2020-10-28 2023-07-03 이케나 온콜로지, 인코포레이티드 Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
CA3202523A1 (en) 2020-12-02 2022-06-09 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
KR20230121800A (ko) 2020-12-17 2023-08-21 트러스티즈 오브 터프츠 칼리지 Fap-활성화된 래디오테라노스틱스, 및 이와 관련된용도
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
EP4281102A1 (en) 2021-01-22 2023-11-29 Mendus B.V. Methods of tumor vaccination
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
CA3210196A1 (en) 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CN116761822A (zh) * 2021-02-10 2023-09-15 上海济煜医药科技有限公司 抗pd-1抗体及其用途
TW202246324A (zh) 2021-03-01 2022-12-01 美商艾希利歐發展股份有限公司 用於治療癌症的經掩蔽之ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
PE20241732A1 (es) * 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216979A1 (en) 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117412767A (zh) 2021-05-25 2024-01-16 雪绒花免疫公司 C-x-c基序趋化因子受体6（cxcr6）结合分子及其使用方法
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
TW202313679A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
JP2024527049A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド がんを治療するための方法及び組成物
JP2024529502A (ja) 2021-07-30 2024-08-06 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
MX2024005722A (es) 2021-11-12 2024-05-28 Novartis Ag Terapia de combinacion para el tratamiento del cancer de pulmon.
JP2024541508A (ja) 2021-11-24 2024-11-08 ジェネンテック， インコーポレイテッド 治療用インダゾール化合物およびがんの治療における使用方法
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
US12275745B2 (en) 2021-11-24 2025-04-15 Genentech, Inc. Therapeutic compounds and methods of use
US20240294926A1 (en) 2021-12-16 2024-09-05 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
CN114456262B (zh) * 2022-01-13 2024-06-11 浙江大学医学院附属第一医院 抗h1n1流感病毒核蛋白单克隆抗体zju-np-a1及其在检测中的应用
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
MX2024010310A (es) 2022-02-25 2024-08-28 Bristol Myers Squibb Co Terapia de combinacion para carcinoma colorrectal.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CA3254481A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag USE OF ANTI-CLAUDIN-1 ANTIBODIES TO INCREASE T LYMPHOCYTE AVAILABILITY
WO2023173091A1 (en) 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
KR20240169042A (ko) 2022-04-01 2024-12-02 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
IL315992A (en) 2022-04-08 2024-11-01 Bristol Myers Squibb Co Identification, classification and quantification of tertiary lymphoid structures using machine learning
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2022458320A1 (en) 2022-05-11 2024-11-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
AU2023269545A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
EP4554978A1 (en) 2022-07-13 2025-05-21 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20260015356A1 (en) 2022-07-14 2026-01-15 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
IL318252A (en) 2022-07-19 2025-03-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
JP2025526369A (ja) 2022-07-27 2025-08-13 アストラゼネカ・アクチエボラーグ Ｐｄ－１／ｐｄ－ｌ１阻害剤を有するインターロイキン１２を発現する組換えウイルスの組み合わせ
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
JP2025533015A (ja) 2022-09-30 2025-10-03 アレンティス セラピューティクス アクチェンゲゼルシャフト 薬物抵抗性肝細胞癌の処置
EP4599089A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
AU2023403103A1 (en) 2022-12-01 2025-07-10 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
AU2023408612A1 (en) 2022-12-20 2025-07-03 BioNTech SE Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
IL321575A (en) 2022-12-21 2025-08-01 Bristol Myers Squibb Co Combination therapy for lung cancer
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
CN120957721A (zh) 2023-02-14 2025-11-14 莫菲克医疗股份有限公司 抑制αvβ8整合素
EP4665458A1 (en) 2023-02-14 2025-12-24 Morphic Therapeutic, Inc. Inhibiting alpha v beta8 integrin
WO2024175699A1 (en) 2023-02-23 2024-08-29 Imcheck Therapeutics Combination of btn3a activating antibody and immune checkpoint inhibitors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2024215787A1 (en) 2023-04-11 2024-10-17 Ngm Biopharmaceuticals, Inc. Methods of treating osteosarcoma using lair1 binding agents and pd-1 antagonists
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
IL324490A (en) 2023-05-10 2026-01-01 Genentech Inc Methods and preparations for treating cancer
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
CN121605130A (zh) 2023-06-23 2026-03-03 感应检查疗法公司 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2025021073A1 (zh) 2023-07-21 2025-01-30 江苏迈威康新药研发有限公司 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025128264A1 (en) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anti-pd-1 monoclonal antibody and methods of use thereof
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025155607A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025222087A2 (en) * 2024-04-19 2025-10-23 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
US20250381225A1 (en) * 2024-06-14 2025-12-18 Development Center For Biotechnology Recombinant antibodies, chimeric antigen receptors, and uses thereof in treating cancers
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DK0557459T3 (da) 1990-11-13 1997-12-15 Immunex Corp Bifunktionelle, selekterbare fusionsgener
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
JP3871326B2 (ja) 2000-11-15 2007-01-24 小野薬品工業株式会社 Ｐｄ−１欠損マウスおよびその用途
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
CN104436190A (zh) * 2005-06-08 2015-03-25 达纳-法伯癌症研究院公司 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
EP1907001B1 (en) * 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
WO2007100098A1 (ja) 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
CA2687377C (en) 2007-05-30 2013-05-14 Genexine Co., Ltd. Immunoglobulin fusion proteins
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009014708A2 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2307050A4 (en) 2008-07-04 2012-07-25 Ono Pharmaceutical Co USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
ES2629337T3 (es) * 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20130035472A1 (en) 2010-03-17 2013-02-07 Anaptysbio, Inc. Method of producing transcripts using cryptic splice sites
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
US20130217656A1 (en) 2010-08-12 2013-08-22 Beth Israel Deaconess Medical Center Inc Methods and compositions for diagnosing and treating lupus
US20130310266A1 (en) 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
CA2830806C (en) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN107519486B (zh) 2011-06-24 2021-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
WO2013177102A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
WO2013174997A1 (en) 2012-05-25 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
KR102243062B1 (ko) * 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EP3122779B1 (en) 2014-03-24 2019-05-22 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
HUE048677T2 (hu) 2014-06-19 2020-07-28 Regeneron Pharma Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
JP6313530B1 (ja) 2015-01-16 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 標的化成分及びエフェクター成分を有する分子構築物
EP3666794A1 (en) * 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)

Also Published As

Publication number Publication date
SI2992017T1 (sl) 2021-04-30
WO2014179664A3 (en) 2015-02-19
CA2910278A1 (en) 2014-11-06
RS61400B1 (sr) 2021-02-26
AU2014259719B2 (en) 2019-10-03
HRP20210122T1 (hr) 2021-04-16
WO2014179664A2 (en) 2014-11-06
SMT202100065T1 (it) 2021-03-15
HUS2100031I1 (hu) 2021-09-28
PT2992017T (pt) 2021-01-29
EP2992017A2 (en) 2016-03-09
EP2992017A4 (en) 2017-03-29
HK1219743A1 (zh) 2017-04-13
CA2910278C (en) 2021-09-28
KR20160034247A (ko) 2016-03-29
RU2723050C2 (ru) 2020-06-08
SG11201508528TA (en) 2015-11-27
US20160075783A1 (en) 2016-03-17
MX372817B (es) 2020-07-03
AU2019240593B2 (en) 2021-06-10
LUC00232I2 (pl) 2025-02-03
NZ753073A (en) 2021-11-26
KR102243062B1 (ko) 2021-04-21
DK2992017T3 (da) 2021-01-25
JP6742903B2 (ja) 2020-08-19
NL301120I2 (nl) 2021-11-15
RU2015151505A (ru) 2017-06-07
CY1123935T1 (el) 2022-03-24
CN105339389B (zh) 2021-04-27
LTC2992017I2 (pl) 2024-04-10
RU2015151505A3 (pl) 2018-03-20
BR112015026823A2 (pt) 2017-09-05
US20210163589A1 (en) 2021-06-03
CN105339389A (zh) 2016-02-17
EP2992017B1 (en) 2020-11-18
CY2021023I2 (el) 2022-03-24
NO2021043I1 (no) 2021-09-28
US20180051082A1 (en) 2018-02-22
US10738117B2 (en) 2020-08-11
JP2016523516A (ja) 2016-08-12
MX2015015037A (es) 2016-07-08
JP7009543B2 (ja) 2022-01-25
LT2992017T (lt) 2021-02-25
HUE053069T2 (hu) 2021-06-28
EP3770176A1 (en) 2021-01-27
ES2845609T3 (es) 2021-07-27
JP2020115874A (ja) 2020-08-06
AU2014259719A1 (en) 2015-12-17
AU2019240593A1 (en) 2019-10-24
US20230331843A1 (en) 2023-10-19
US9815897B2 (en) 2017-11-14
LTPA2021011I1 (pl) 2021-10-25
NL301120I1 (pl) 2021-08-18
NZ714537A (en) 2021-09-24
CY2021023I1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
CY2021023I1 (el) Αντισωματα κατευθυνομενα εναντι προγραμματισμενου θανατου-1 (pd-1)
HUS2400016I1 (hu) FCRN elleni antitestek
IL280766A (en) Antibodies directed against programmed death- 1 (pd-1)
DK3334824T3 (da) Pd-1-antistoffer
DK3336106T3 (da) Anti-fcrh5-antistoffer
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3201230T3 (da) Canine pd-l1-bindende pd-l1-antistoffer
PT3071595T (pt) Anticorpo anti calicreína-2 humanizado
EP3056613C0 (en) SHOVEL
DK3613286T3 (da) Fælde
EP2806125A4 (en) Wheel loader
DK3068800T3 (da) FcRn-specifikke antistoffer
ME03094B (me) Protutijela protiv kemokina pan-elr+ схс
EP2928075A4 (en) CLASS-D AMPLIFIER
DK3065774T3 (da) Anti-CCL17-antistoffer
FI20135593A7 (fi) Huuva
DK3080385T3 (da) Forbedret lukkeapparat
UA25336S (uk) Коток польовий
EP2973252A4 (en) TRANSPLANT PROCEDURE
UA26771S (uk) Капот
UA26772S (uk) Капот
UA26586S (uk) Капот
UA26769S (uk) Капот
UA27666S (uk) Черпак